Bryan, Garnier & Co acts as Placement Agent for Cardio3 BioScience’s €32m Capital Raise

Paris, February 27th, 2015 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful private placement of 713,380 new ordinary shares to institutional investors of Cardio3 Biosciences for an amount of €32m. Bryan, Garnier & Co acted as Placement Agent alongside UBS Investment Bank and Petercam.

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced it had raised approximately €32 million through a private placement of ordinary shares to investors in the United States and Europe.

Cardio3 BioSciences has placed 713,380 new shares to qualified institutional investors in the United States and Europe for €44.50 per share, with no discount to the previous day closing price and a 4% premium to the last 30-day average price. The placed shares represent 10% of the current number of outstanding shares, bringing the total number of shares outstanding after the issue to 7,847,187. The new shares are expected to be admitted to trading on Euronext Brussels and Paris following their issuance, which is expected to take place on Tuesday, March 3rd 2015. 40% of the placement was made on the US market, through à 144A placement.

Cardio3 BioSciences will use the proceeds from the private placement to:

• Further develop its newly acquired CAR-T cell technology platform;
• Strengthen the leadership of C-Cure® for the treatment of congestive heart failure, and;
• For general corporate purposes.

For the past 18 years, Bryan, Garnier & Co has been one of the leading European placement agents for growth capital, with more than 50 transactions led, including late-stage venture, development stage financings, IPOs, follow-on offerings as well as PIPEs. In 2014, Bryan, Garnier & Co led the €100m private placement for Mérieux NutriSciences, the largest European growth equity financing in the healthcare sector. Recent growth financing transactions led by Bryan, Garnier & Co include the €37m IPO of Bone Therapeutics on Euronext, the £100m IPO of Quantum Pharma on the LSE, the $133m IPO of DBV Technologies on Nasdaq and the €25m private placement for the software company Jahia.

Jean-Christophe Renondin, Managing Director Healthcare, stated: “The success of the Book Building placement of Cardio3 BioSciences reiterates Bryan Garnier international health care franchise and the strong commitment of our teams to support innovative growth companies. Bryan Garnier is very proud of supporting the Cardio3 BioSciences team in this significant value-creation step.”

Cédric Moreau, Director ECM Healthcare, added: “The global offering was strongly oversubscribed in both Europe and the US. Once again, Bryan Garnier played a key role in a cross-border ECM Healthcare transaction. We expect this success to confirm positive investors’ sentiment on the European Healthcare industry where a number of key catalysts are expected this year.”

For more information, please contact:

Hervé Ronin

Partner – Healthcare Corporate Finance

hronin@bryangarnier.com | + 33 156687522

 Jean-Christophe Renondin

Managing Director – Healthcare Corporate Finance

hronin@bryangarnier.com | + 33 156687504

Cédric Moreau

Director – Healthcare Equity Capital Markets

cmoreau@bryangarnier.com | + 33 156687565

Christian Finan

Director – Equity Capital Markets

cfinan@bryangarnier.com | + 33 156687530

About Cardio3 Biosciences 

Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA), and Dartmouth College (NH, USA). The Company’s lead product candidate in cardiology is C-Cure®, an autologous stem cell therapeutic using adult-guided stem cells for the condition of congestive heart failure. The Company’s lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumour types, including hematologic cancers and solid tumours. Cardio3 BioSciences is also developing a portfolio of medical devices for enhancing the delivery of biotherapeutic agents into the myocardium (C-Cathez®) and for cardiac surgery involving mitral valve defects. Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

(www.c3bs.com)